Document is current

Article History

Accepted: 4 September 2022

First Online: 17 September 2022

Declarations

:

: No external funding was used in the preparation of this manuscript.

: Nicola Personeni has received consulting fees from Amgen, Merck Serono, and Servier; lectures fees from AbbVie, Gilead, Lilly, and Sanofi; travel expenses from Amgen and ArQule; and institutional research funding from Basilea, Merck Serono, and Servier. Lorenza Rimassa has received consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Servier, Taiho Oncology, and Zymeworks; lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, and Sanofi; travel expenses from AstraZeneca; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, and Zymeworks. Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Ester Oneda, Daniele Lavacchi, Francesca Ratti, Federica Pedica, Angelo Della Corte, Mara Persano, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, and Andrea Casadei-Gardini declare they have no conflicts of interest that might be relevant to the contents of this manuscript.

: The Ethical Review Board of each institutional hospital approved the present study. This study was performed in line with the principles of the Declaration of Helsinki.

: Patients provided informed consent for treatment with ivosidenib, which is not yet approved in Italy. Under the conditions of retrospective archival tissue collection and anonymization of patients’ data, our study was exempted from the acquisition of informed consent for retrospective data analysis from patients, by the Institutional Review Board.

: Not applicable.

: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

: Not applicable.

: Study conception and design: MR, AC-G. Acquisition of data (acquired and managed patients): All authors. Analysis and interpretation of data: MR, AC-G. Writing, review, and/or revision of the manuscript: All authors. Final approval of the manuscript: All authors.